- 5-MeO-DALT
- 5-Methoxy-N,N-diallyltryptamine
- 3-[2-(Diallylamino)ethyl]-5-methoxyindole
- N,N-Diallyl-5-methoxytryptamine
- Indole, 3-[2-(diallylamino)ethyl]-5-methoxy
- 5-Methoxy-DALT
- Tryptamine, N,N-diallyl-5-methoxy
Brandt, SD; Tirunarayanapuram, SS; Freeman, S; Dempster, N; Barker, SA; Daley, PF; Cozzi, NV; Martins, CPB. Microwave-accelerated synthesis of psychoactive deuterated N,N-dialkylated-[α,α,β,β-d4]-tryptamines J. Labelled Compd. Radiopharm., 1 Nov 2008, 51 (14), 423–429. 169 kB. https://doi.org/10.1002/jlcr.1557 #11 MS,NMR
Corkery, JM; Durkin, E; Elliott, S; Scchifano, F; Ghodse, AH. The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review Prog. Neuro-Psychopharmacol. Biol. Psych., 1 Dec 2012, 39 (1), 259–262. 307 kB. https://doi.org/10.1016/j.pnpbp.2012.05.022
Jovel, A; Felthous, A; Bhattacharyya, A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT J. Forensic Sci., 1 May 2014, 59 (3), 844–846. 91 kB. https://doi.org/10.1111/1556-4029.12367
Brandt, SD; Kavanagh, PV; Dowling, G; Talbot, B; Westphal, F; Meyer, MR; Maurer, HH; Halberstadt, AL. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives Drug Test. Anal., 1 Jan 2017, 9 (1), 115-126. 1.3 MB. https://doi.org/10.1002/dta.1974
Arunotayanun, W; Dalley, JW; Huang, X; Setola, V; Treble, R; Iversen, L; Roth, BL; Gibbons, S. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: Emerging ‘novel psychoactive drugs’ Bioorg. Med. Chem. Lett., 1 Jun 2013, 23 (11), 3411-3415. 1.1 MB. https://doi.org/10.1016/j.bmcl.2013.03.066 #18
Dinger, J; Woods, C; Brandt, SD; Meyer, MR; Maurer, HH. Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class Toxicol. Lett., 1 Jan 2016, 241, 82-94. 2.6 MB. https://doi.org/10.1016/j.toxlet.2015.11.013
Cozzi, NV; Daley, PF. Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines Bioorg. Med. Chem. Lett., 1 Feb 2016, 26 (3), 959-964. 574 kB. https://doi.org/10.1016/j.bmcl.2015.12.053 #6
Meyer, MR; Caspar, A; Brandt, SD; Maurer, HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches Anal. Bioanal. Chem., 1 Jan 2014, 406 (1), 225–237. 457 kB. https://doi.org/10.1007/s00216-013-7425-9 #5-MeO-DALT LC,MS
Brandt, SD; Martins, CPB. Analytical methods for psychoactive N,N-dialkylated tryptamines Trends Anal. Chem., 1 Sep 2010, 29 (8), 858–869. 446 kB. https://doi.org/10.1016/j.trac.2010.04.008 #40
Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra BLOTTER, 1 Mar 2018, 3 (1). 1.2 MB. https://doi.org/10.16889/isomerdesign-5 #T24 NMR
Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. Supplementary Data BLOTTER, 1 Mar 2018, 3 (1). 5.7 MB. https://doi.org/10.16889/isomerdesign-5-supp #T24 NMR
Klein, LM; Cozzi, NV; Daley, PF; Brandt, SD; Halberstadt, AL. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs Neuropharmacology, 1 Nov 2018, 142, 231-239. 753 kB. https://doi.org/10.1016/j.neuropharm.2018.02.028
Caspar, AT; Gaab, JB; Michely, JA; Brandt, SD; Meyer, MR; Maurer, HH. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC–MS, LC–MSn, and LC-HR-MSMS Drug Test. Anal., 1 Jan 2018, 10 (1), 184–195. 546 kB. https://doi.org/10.1002/dta.2197
Jones, LE; Stewart, A; Peters, KL; McNaul, M; Speers, SJ; Fletcher, NC; Bell, SEJ. Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples Analyst, 25 Jan 2016, 141 (3), 902–909. 1.3 MB. https://doi.org/10.1039/c5an02326b NMR,other
Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products Drug Test. Anal., 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315
Nichols, DE. Chemistry and structure–activity relationships of psychedelics In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 1-43. 2.6 MB. https://doi.org/10.1007/7854_2017_475 #18
Taschwer, M; Ebner, E; Schmid, MG. Test purchase of new synthetic tryptamines via the Internet: Identity check by GC-MS and separation by HPLC J. Appl. Pharm. Sci., 1 Jan 2016, 6 (1), 028–034. 504 kB. https://doi.org/10.7324/JAPS.2016.600105 GC,LC,MS
Nagai, F; Nonaka, R; Kamimura, KSH. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain Eur. J. Pharmacol., 22 Mar 2007, 559 (2), 132–137. 399 kB. https://doi.org/10.1016/j.ejphar.2006.11.075 #5-MeO-DALT
Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #5-MeO-DALT GC,LC,MS,UV
Seto, T; Takahashi, M; Nagashima, M; Suzuki, J; Yasuda, I. The identifications and the aspects of the commercially available uncontrolled drugs purchased between Apr. 2003 and Mar. 2004 Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2005, 56 75–80. 1.2 MB. #5-MeO-DALT MS,NMR,UV
EMCDDA. New drugs in Europe, 2007, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2008. 381 kB. #2
Halberstadt, AL; Chatha, M; Klein, AK; Wallach, J; Brandt, SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species Neuropharmacology, 1 May 2020, 167, 107933. 2.4 MB. https://doi.org/10.1016/j.neuropharm.2019.107933 #5-MeO-DALT
Sexton, JD; Nichols, CD; Hendricks, PS. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics Front. Psychiatry, 11 Feb 2020, 10 (896). 529 kB. https://doi.org/10.3389/fpsyt.2019.00896 #5-MeO-DALT
Clancy, L; Philp, M; Shimmon, R; Fu, S. Development and validation of a color spot test method for the presumptive detection of 25-NBOMe compounds Drug Test. Anal., 19 Aug 2020, 13 (5), 929-943. 11.3 MB. https://doi.org/10.1002/dta.2905 #5-methoxy-N,N-diallyltryptamine spot
WHO. WHO Expert Committee on Drug Dependence: Forty-third Report World Health Organization, 1 Jan 2021. 1.9 MB. #5-MeO-DALT
Kikura-Hanajiri, R; Kawamura, M; Uchiyama, N; Ogata, J; Kamakura, H; Saisho, K; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part I: GC-MS and LC-MS Yakugaku Zasshi, 1 Jun 2008, 128 (6), 971–979. 1.4 MB. https://doi.org/10.1248/yakushi.128.971 #5-MeO-DALT Incorrect structures drawn. Corrected structures in errata page at end. GC,LC,MS,UV
Uchiyama, N; Kawamura, M; Kamakura, H; Kikura-Hanajiri, R; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part II: Color test and TLC Yakugaku Zasshi, 1 Jan 2008, 128 (6), 981–987. 406 kB. https://doi.org/10.1248/yakushi.128.981 #5-MeO-DALT TLC
Philp, M; Shimmon, R; Stojanovska, N; Tahtouh, M; Fu, S. Development and validation of a presumptive colour spot test method for the detection of piperazine analogues in seized illicit materials Anal. Methods, 1 Jan 2013, 5 (20), 5402. 783 kB. https://doi.org/10.1039/c3ay40511g #5-Methoxy-N,N,-diallyltryptamine MS,NMR,IR,spot